US Patent

US11951097 — Methods of treating multiple sclerosis

Method of Use · Assigned to Vanda Pharmaceuticals Inc · Expires 2042-10-10 · 16y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods of treating multiple sclerosis, including methods for reducing clinical management events before or during treatment.

USPTO Abstract

The disclosure relates to methods of treating multiple sclerosis. Also provided are pharmaceutical products containing ponesimod, instructions for use of ponesimod, methods for selling a drug product containing ponesimod, and methods for reducing clinical management events before or during treatment of multiple sclerosis.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3891 —
U-3891 —
U-3891 —
U-3891 —
U-3891 —
U-3891 —
U-3891 —
U-3891 —
U-3891 —
U-3891 —

Patent Metadata

Patent number
US11951097
Jurisdiction
US
Classification
Method of Use
Expires
2042-10-10
Drug substance claim
No
Drug product claim
No
Assignee
Vanda Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.